Repurposing drugs for treatment of tuberculosis: A role for non-steroidal anti-inflammatory drugs

British Medical Bulletin

Volumn 118, Issue 1, 2016, Pages 138-148

  Maitra, Arundhati ^a   Bates, Sadcrossed D Sign ^a   Shaik, Monisha ^a   Evangelopoulos, DImitrios ^b   Abubakar, Ibrahim ^b   McHugh, Timothy D ^b   Lipman, Marc ^b   Bhakta, Sanjib ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antimicrobial resistance; Carprofen; Drug repurposing; Mycobacterium; NSAIDs; Tuberculosis

Indexed keywords

ACETYLSALICYLIC ACID; CARPROFEN; CELECOXIB; DICLOFENAC; IBUPROFEN; METAL COMPLEX; NONSTEROID ANTIINFLAMMATORY AGENT; OXYPHENBUTAZONE; ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG REPOSITIONING; HUMAN; IMMUNOMODULATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT OUTCOME; TUBERCULOSIS; DRUG EFFECTS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTITUBERCULAR AGENTS; DRUG REPOSITIONING; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84976497627     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldw019     Document Type: Article

References (72)

1. Organization WH. Global tuberculosis report 2015. 2015.
2. Burman WJ. Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century. Clin Infect Dis 2010;50:S165-72.
3. Maitra A, Bhakta S. TB summit 2014: prevention, diagnosis, and treatment of tuberculosis-a meeting report of a euroscicon conference. Virulence 2014;5:638-44.
4. Maitra A, Danquah CA, Scotti F, et al. Tackling tuberculosis: insights from an international TB summit in London. Virulence 2015;6:581-92.
5. Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29-40.
6. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006;25:420-8.
7. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83.
8. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013;12:388-404.
9. Languillon J. The effects ot thalidomide on leprosy reaction. Int J Lepr 1971;39:590-2.
10. Schoeman JF, Fieggen G, Seller N, et al. Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol 2006;21: 301-8.
11. Oprea TI, Mestres J. Drug repurposing: far beyond new targets for old drugs. AAPS J 2012;14:759-63.
12. Kinnings SL, Xie L, Fung KH, et al. The mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol 2010;6:e1000976.
13. Palomino JC, Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J Antimicrob Chemother 2013;68:275-83.
14. Gillespie SH, Crook AM, McHugh TD, et al. Fourmonth moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014;371:1577-87.
15. Maitra A, Bates S, Kolvekar T, et al. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis. Int J Infect Dis 2015;32:50-5.
16. Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant mycobacterium tuberculosis infections. Int J Antimicrob Agents 2012;39:376-80.
17. Gupta S, Cohen KA, Winglee K, et al. Efflux inhibition with verapamil potentiates bedaquiline in mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:574-6.
18. Maiga M, Ammerman NC, Maiga MC, et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 2013;208:512-9.
19. Gold B, Pingle M, Brickner SJ, et al. Nonsteroidal antiinflammatory drug sensitizes mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci USA 2012;109:16004-11.
20. Guzman JD, Evangelopoulos D, Gupta A, et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi wholecell phenotypic assay. BMJ Open 2013;3:e002672.
21. Ivanyi J, Zumla A. Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment. J Infect Dis 2013;208:185-8.
22. Lee YT, Wang Q. Inhibition of hKv2.1, a major human neuronal voltage-gated K+ channel, by meclofenamic acid. Eur J Pharmacol 1999;378:349-56.
23. Neal TM, Vissers MC, Winterbourn CC. Inhibition by nonsteroidal anti-inflammatory drugs of superoxide production and granule enzyme release by polymorphonuclear leukocytes stimulated with immune complexes or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol 1987;36:2511-7.
24. Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci 2010;2:19.
25. Shirin H, Moss SF, Kancherla S, et al. Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against helicobacter pylori. J Gastroenterol Hepatol 2006;21:1388-93.
26. Hersh E, Hammond B, Fleury A. Antimicrobial activity of flurbiprofen and ibuprofen in vitro against six common periodontal pathogens. J Clin Dent 1990;3:1-5.
27. Mazumdar K, Dastidar SG, Park JH, et al. The antiinflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target. Eur J Clin Microbiol Infect Dis 2009;28:881-891.
28. Dutta NK, Mazumdar K, Dastidar SG, et al. Activity of diclofenac used alone and in combination with streptomycin against mycobacterium tuberculosis in mice. Int J Antimicrob Agents 2007;30:336-40.
29. Sriram D, Yogeeswari P, Devakaram RV. Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides. Bioorg Med Chem 2006;14:3113-8.
30. Dutta NK, Mazumdar K, Seok SH, et al. The antiinflammatory drug diclofenac retains anti-listerial activity in vivo. Lett Appl Microbiol 2008;47:106-11.
31. Chiniforoshan H, Tabrizi L, Hadizade M, et al. Antiinflammatory drugs interacting with Zn (II) metal ion based on thiocyanate and azide ligands: synthesis, spectroscopic studies, DFT calculations and antibacterial assays. Spectrochim Acta A Mol Biomol Spectrosc 2014;128:183-90.
32. Kovala-Demertzi D, Dokorou V, Primikiri A, et al. Organotin meclofenamic complexes: synthesis, crystal structures and antiproliferative activity of the first complexes of meclofenamic acid-novel anti-tuberculosis agents. J Inorg Biochem 2009;103:738-44.
33. Niu L, Li Y, Li Q. Medicinal properties of organotin compounds and their limitations caused by toxicity. Inorganica Chim Acta 2014;423:2-13.
34. Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-49.
35. Inman WH. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br Med J 1977;1:1500-5.
36. Kalle AM, Rizvi A. Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor. Antimicrob Agents Chemother 2011;55:439-42.
37. Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 2002;277:38915-20.
38. Salunke SB, Azad AK, Kapuriya NP, et al. Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore. Bioorg Med Chem 2015;23: 1935-43.
39. Byrne ST, Denkin SM, Zhang Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J Antimicrob Chemother 2007;59:313-6.
40. Schaller A, Sun Z, Yang Y, et al. Salicylate reduces susceptibility of mycobacterium tuberculosis to multiple antituberculosis drugs. Antimicrob Agents Chemother 2002;46:2636-9.
41. Byrne ST, Denkin SM, Zhang Y. Aspirin antagonism in isoniazid treatment of tuberculosis in mice. Antimicrob Agents Chemother 2007;51:794-5.
42. Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci 2010;293:12-7.
43. Evangelopoulos D, Bhakta S. Rapid methods for testing inhibitors of mycobacterial growth, 2nd edn, Springer: Antibiotic Resistance Protocols, 2010;193-201.
44. Gupta A, Bhakta S. An integrated surrogate model for screening of drugs against mycobacterium tuberculosis. J Antimicrob Chemother 2012;67:1380-91.
45. Danquah CA, AM, Gibbons S, et al. HT-SPOTi: a rapid, drug susceptibility test (DST), to evaluate antibiotic resistance profiles and novel chemicals for anti-infective drug discovery. Curr Protoc Microbiol 2016;8:17-8.
46. Sanyal A, Roy D, Chowdhury B, et al. Ibuprofen, a unique anti?inflammatory compound with antifungal activity against dermatophytes. Lett Appl Microbiol 1993;17:109-11.
47. Elvers K, Wright S. Antibacterial activity of the antiinflammatory compound ibuprofen. Lett Appl Microbiol 1995;20:82-4.
48. Vilaplana C, Marzo E, Tapia G, et al. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013;208:199-202.
49. Eisen DP, McBryde ES, Walduck A. Low-dose aspirin and ibuprofen's sterilizing effects on mycobacterium tuberculosis suggest safe new adjuvant therapies for tuberculosis. J Infect Dis 2013;208:1925-7.
50. Konstan MW, Krenicky JE, Finney MR, et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003;306:1086-91.
51. Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother 2010;44: 489-506.
52. Davies NM. Clinical pharmacokinetics of ibuprofen. Clin Pharmacokinet 1998;34:101-54.
53. Rainsford K. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 2009;17:275-342.
54. Carprofen Summary Report (1). In: EMEA (ed). Committee for Veterinary Medicinal Products. London, UK: 1999.
55. Crevoisier C. Pharmacokinetic properties of carprofen in humans. Eur J Rheumatol Inflamm 1982;5:492-502.
56. Kerr A, Muller F, Ferguson J, et al. Occupational carprofen photoallergic contact dermatitis. Br J Dermatol 2008;159:1303-8.
57. Roelandts R. Photosensitivity associated with carprofen. Dermatologica 1986;172:64-5.
58. Bosca F, Miranda MA. Photosensitizing drugs containing the benzophenone chromophore. J Photochem Photobiol B 1998;43:1-26.
59. Ingrao JC, Johnson R, Tor E, et al. Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. J Am Assoc Lab Anim Sci 2013; 52:553-9.
60. Brentnall C, Cheng Z, McKellar QA, et al. Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. J Vet Pharmacol Ther 2013;36:320-8.
61. Organization WH. Treatment of tuberculosis: guidelines. Geneva: World Health Organization, 2010.
62. Simonetti A, Marzi S, Billas IM, et al. Involvement of protein IF2 N domain in ribosomal subunit joining revealed from architecture and function of the fulllength initiation factor. Proc Natl Acad Sci USA 2013; 110: 15656-61.
63. Denkin S, Byrne S, Jie C, et al. Gene expression profiling analysis of mycobacterium tuberculosis genes in response to salicylate. Arch Microbiol 2005;184:152-7.
64. Yin Z, Wang Y, Whittell LR, et al. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem Biol 2014;21:481-7.
65. Gui W-J, Lin S-Q, Chen Y-Y, et al. Crystal structure of DNA polymerase III ? sliding clamp from mycobacterium tuberculosis. Biochem Biophys Res Commun 2011;405:272-7.
66. Arbex MA, Varella MdCL, Siqueira HRd, et al. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations-part 2: second line drugs. J Bras Pneumol 2010;36:641-56.
67. Kaufmann SH, Dorhoi A. Inflammation in tuberculosis: interactions, imbalances and interventions. Curr Opin Immunol 2013;25:441-9.
68. Flynn JL, Chan J, Lin PL. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol 2011;4:271-8.
69. Hickey A, Durham P, Dharmadhikari A, et al. Inhaled drug treatment for tuberculosis: past progress and future prospects. J Control Release 2015 (in Press corrected proof).
70. Gelperina S, Kisich K, Iseman MD, et al. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005;172:1487-90.
71. Hariyadi DM, Lin SC-Y, Wang Y, et al. Diffusion loading and drug delivery characteristics of alginate gel microparticles produced by a novel impinging aerosols method. J Drug Target 2010;18:831-41.
72. Bartzatt R, Cirillo SL, Cirillo JD. Determination of molecular properties effectuating the growth inhibition of mycobacterium tuberculosis by various small molecule hydrazides. Lett Drug Des Discov 2008;5: 162-8.